Aytu BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AYTU research report →
Price Chart
About the company
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U. S.
- CEO
- Joshua R. Disbrow
- IPO
- 2008
- Employees
- 76
- HQ
- Denver, CO, US
Get TickerSpark's AI analysis on AYTU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.91M
- P/E
- -1.49
- Fwd P/E
- 13.53
- PEG
- 0.02
- P/S
- 0.49
- P/B
- 1.63
- EV/EBITDA
- -1.49
- Div Yield
- 0.00%
- Gross Margin
- 61.14%
- Op Margin
- -18.35%
- Net Margin
- -34.34%
- ROE
- -69.19%
- ROIC
- -19.91%
Latest fiscal year · YoY change
- Revenue
- $57.57M-13.3%
- Gross Profit
- $36.82M-19.7%
- Op Income
- $-8,315,000
- Net Income
- $-14,252,000-5.1%
- EPS
- $-1.16+46.3%
- OCF Growth
- +269.4%
- FCF Growth
- +163.0%
- 52W High
- $3.07
- 52W Low
- $1.75
- 50D MA
- $2.04
- 200D MA
- $2.27
- Beta
- 0.27
- RSI (14)
- 80
- Avg Volume
- 139.68K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aytu ended fiscal 2026 with EXXUA gaining traction, ADHD remaining durable, and adjusted EBITDA turning positive in the fourth quarter.· September 22, 2026
- EXXUA fourth-quarter net revenue was $3.9 million, up from $2.4 million in Q3, as prescriptions rose to 3,323 from 1,398 in the March quarter.
- Management said EXXUA gross-to-net has been better than initially expected, driven by higher-than-modeled commercial approval rates and a growing mix of government payers.
- The ADHD franchise outperformed expectations, with Q4 net revenue of $10.4 million versus $9.1 million in Q3 and $13.1 million a year ago.
- Consolidated Q4 revenue was $16.1 million, up 6% year over year, and adjusted EBITDA was positive $0.5 million.
- For fiscal 2027, Aytu guided to $49 million to $54 million of GAAP operating expenses and said it expects positive adjusted EBITDA over the six months ending June 30, 2027.
Fourth-quarter fiscal 2026 net revenue was $16.1 million, up 6% from $15.1 million in the prior-year period and up from $12.4 million in Q3. Full-year fiscal 2026 net revenue was $57.6 million. Q4 gross profit was $10.4 million, with gross margin of approximately 65% versus $10.3 million and 68% a year ago; full-year gross profit was $36.8 million, or 64%. Q4 net loss was $0.1 million, or $0.00 per share, versus a net loss of $19.8 million, or $2.92 per share, a year ago; adjusted EBITDA was positive $0.5 million. Full-year net loss was $14.3 million and adjusted EBITDA was negative $3.7 million. Cash and cash equivalents were $26.3 million at June 30, and the revolver balance was reduced to $6.1 million from $10.4 million at March 31 before being repaid after quarter-end. For fiscal 2027, management did not provide revenue guidance, but expects GAAP operating expenses of approximately $49 million to $54 million, cash-based operating expenses of $45 million to $49 million, and consolidated gross margin to improve through the year toward 66% to 67% in Q4. Management expects lower adjusted EBITDA and operating cash flow in the first half of fiscal 2027 than the second half, with positive adjusted EBITDA over the six months ending June 30, 2027.
Josh Disbrow emphasized that EXXUA is the company’s main growth engine and said the launch is beginning to show up in real-world prescribing, refill activity, and physician feedback. He framed the launch as methodical rather than spend-at-all-costs, stressing productivity, return on investment, and cash preservation. His tone was upbeat and confident, but also disciplined: management is adjusting the sales force in real time, holding reps accountable, and expanding only as cash flow allows.
Ryan Selhorn focused on the improving financial base and the outlook for fiscal 2027. He highlighted Q4 revenue of $16.1 million, gross margin of about 65%, positive adjusted EBITDA of $0.5 million, and cash of $26.3 million at quarter-end, while noting that operating cash flow for fiscal 2026 was positive $3.3 million and that financing outflows were used to reduce debt. He said EXXUA’s gross-to-net remains favorable versus launch assumptions, full-year interest expense declined to $1.9 million from $3.7 million, and the company expects to spend up to $6 million on sales and marketing in fiscal 2027, with margin improving through the year.
Analysts focused on EXXUA economics, reimbursement, RxConnect utilization, and whether the company would pursue payer contracts. Management said gross-to-net is better than expected because of high commercial approval rates and a growing government-payer mix, and that prior authorization success is running around 70% on submitted claims. On contracts, Josh Disbrow said Aytu does not feel pressure to proactively contract with commercial or government payers and will only do so if the economics make sense. Analysts also pressed on sales force size and ramp; management said the rep base was about 42, ramp typically takes 6 to 9 months, and the launch remains in early stages.
The bull case from this call is that EXXUA appears to be gaining early commercial momentum with improving prescriptions, repeat prescribing, and better-than-expected reimbursement economics. Management also said the legacy ADHD business remains durable and cash-generative, helping fund the launch while the company reached positive adjusted EBITDA in Q4.
The main risks are that EXXUA is still early in its launch, prescriptions per rep remain uneven, and management acknowledged variability as the sales force is adjusted and new reps ramp over 6 to 9 months. The company also said it will spend more in fiscal 2027, expects first-half EBITDA and cash flow to be weaker than the second half, and noted that quarterly results can be affected by seasonality, working capital timing, and the pace of payer mix changes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.7%
- Shares Outstanding
- 10.87M
- Float Shares
- 9.97M
of shares held by institutions
36 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 1.09M | 0 |
| Stonepine Capital Management, LLC | 964.90K | ▲ 51.98K |
| Awm Investment Company, Inc. | 619.57K | 0 |
| Vanguard Group Inc | 278.58K | 0 |
| Vanguard Capital Management LLC | 261.15K | 0 |
| Crown Advisors Management, Inc. | 200.00K | 0 |
| Geode Capital Management, LLC | 123.67K | ▲ 30.02K |
| Renaissance Technologies LLC | 121.62K | ▲ 16.80K |
| Diadema Partners LP | 67.19K | ▼ 81.36K |
| Two Sigma Investments, LP | 65.51K | ▼ 39.81K |
| Dimensional Fund Advisors LP | 50.05K | ▲ 4.72K |
| Vanguard Fiduciary Trust Co | 48.14K | ▲ 1.10K |
Held by 23 ETFs
Biggest fund positions in AYTU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 28, 26 | Disbrow Joshua R. | other | 30,000 |
| Jul 28, 26 | PYSZCZYMUKA GREG | other | 20,000 |
| Jul 28, 26 | Disbrow Jarrett | other | 15,000 |
| Jul 28, 26 | Selhorn Ryan J | other | 25,000 |
| Jul 28, 26 | LIU VIVIAN H | other | 10,000 |
| Jul 28, 26 | JAIN ABHINAV | other | 10,000 |
| Jul 28, 26 | DOCKERY CARL | other | 10,000 |
| Jul 28, 26 | Donofrio John Jr. | other | 10,000 |
| Jun 30, 25 | DOCKERY CARL | other | 0 |
| Nov 18, 20 | DOCKERY CARL | buy | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AYTU coverage
Recent articles, reports, and earnings notes.
No research on AYTU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AYTU report →$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)
prnewswire.com · Nov 18
Are GLND, RPID, AYTU Obtaining Fair Deals for their Shareholders?
prnewswire.com · Nov 18
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)
globenewswire.com · Nov 17
AYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.
globenewswire.com · Nov 17
Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket
benzinga.com · Nov 17
Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue Estimates
zacks.com · Nov 16
AYTU Stock Alert: Halper Sadeh LLC is Investigating Whether Aytu BioPharma, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com · Nov 16
Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
globenewswire.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.